Novel Approaches in Post-TIL Combination Therapy Development

Time: 12:00 pm
day: Conference Day One R&D Track AM

Details:

• Reintroducing checkpoint inhibitors after TIL, assessing safety and early signs of efficacy
• Setting benchmarks for post-TIL trials using emerging realworld data
• Identifying patient populations who may benefit from follow-up therapies after early TIL use

Speakers:

James Smithy I am a medical oncologist focused exclusively on treating patients with melanoma. I see patients at the Rockefeller Outpatient Pavilion and the David H. Koch Read more